Adsorption treatment in hyperlipidemia.
Clinical LDL- adsorption has made overwhelming progress in recent years. Thus, immunoadsorption with polyclonal anti-LDL-antibodies and chemoadsorption using the dextransulfate system have been applied successfully for selective LDL-removal in routine clinical plasma treatment of hypercholesterolemic patients suffering from coronary artery disease. Clinical pilot studies showed good results using immunoadsorption with anti-LDL-F(ab)-columns. Promising laboratory results have been achieved using immunoadsorption with monoclonal LDL-antibodies, polyacrylate/fractogel and macroporous cellulose. While these systems need a primary separation step for cells and plasma, the integrated plasma separation/adsorption device and the LDL-hemoperfusion module using E 280590 can even treat whole blood. Thus, these systems hold a great promise for the future.
Bosch
T
T
Nephrological Department, University of Munich, Germany.
D001672:Biocompatible Materials; D002482:Cellulose; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000628:therapy*; D007140:Immunoglobulin Fab Fragments; D007163:Immunosorbent Techniques; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification*
D001672:Biocompatible Materials; D007140:Immunoglobulin Fab Fragments; D008077:Lipoproteins, LDL; D002482:Cellulose